Placebo of ILT-101 clinical trials

ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders

This study is looking at a new medicine called ILT-101 for people with autism. It aims to see if low doses of this medicine can change certain immune cells (Tregs) and if these changes are linked to improvements in daily life and social skills.